// App-Quantinova.ai

: Evidence of Long-Lasting Anti-CD19 Activity of Engrafted CD19 Chimeric Antigen Receptor Modified T Cells in a Phase I Study Targeting Pediatrics with Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Futian Ma

Principal Investigators

  • Jin-Yuan Ho

  • Huan Du

  • Fan Xuan

  • Xiaoli Wu

  • Ying Liu

  • Yizhuo Wang

  • Jianmin Luo

  • Jianqiang Li

Medical Centers

  • Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, China

  • Hebei Senlang Biotechnology, Shijiazhuang, China

  • Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved